Saoirse OSullivan

Company: Artelo Biosciences

Job title: Vice President - Translational Sciences

Seminars:

Fatty Acid Binding Protein (FABP) Modulation as a Novel Therapeutic Strategy 2:30 pm

Reviewing how FABPs, particular FABP5, are intracellular carrier proteins of endocannnabinoids, and inhibiting FABP5 decreases endocannabinoid uptake and increases endocannabinoid levels Introduction to ART26.12, the IND-approved lead small molecule FABP5, being developed for pain indications and the involvement of cannabinoid receptor activation in its analgesic effects The broader therapeutic utility of inhibiting FABP5 and other…Read more

day: Day Two

ART27.13, a Peripherally Restricted CB1 Agonist Under Clinical Investigation Targeting Cancer Anorexia & Cachexia Syndrome (CACS) 12:00 pm

Exploring the scientific and clinical validation of ART27.13, a dual CB1/CB2 agonist, through Phase 1 results and its progression to the Phase 2a CAReS Trial for treating CACS Analyzing the formulation of ART27.13, its unique chemical properties, and the intellectual property supporting its peripheral receptor selectivity Assessing the unmet need in cancer anorexia and cachexia…Read more

day: Conference Day 1